opthea
appoint
dr
jeremy
levin
chairman
board
melbourne
australia
globe
newswire
opthea
limited
asx
opt
clinical
stage
biopharmaceutical
company
developing
novel
therapy
treat
highly
prevalent
progressive
retinal
diseases
pleased
announce
jeremy
levin
dphil
mb
bchir
dr
levin
appointed
company
board
directors
effective
october
dr
levin
chairman
chief
executive
officer
ceo
ovid
therapeutics
inc
nasdaq
ovid
concurrently
chairman
biotechnology
innovation
organization
bio
largest
trade
organization
world
represents
biotechnology
industry
prior
founding
ovid
dr
levin
president
ceo
teva
pharmaceutical
industries
ltd
teva
member
executive
committee
squibb
company
dr
levin
joined
bmy
novartis
global
head
strategic
alliances
served
board
directors
various
public
private
biopharmaceutical
companies
including
biocon
ltd
nse
biocon
currently
board
directors
lundbeck
omx
lun
dr
levin
voted
one
influential
biotechnology
leaders
fierce
biotech
one
top
biotechnology
ceos
healthcare
technology
report
august
named
pharmavoice
annual
list
innovative
influential
inspirational
people
life
sciences
industry
recipient
albert
einstein
award
leadership
life
sciences
b
nai
b
rith
award
distinguished
achievement
dr
levin
practiced
medicine
university
hospitals
england
south
africa
switzerland
earned
bachelor
degree
masters
degree
doctorate
university
oxford
subsequently
received
bachelor
medicine
bachelor
surgery
degrees
university
cambridge
mr
geoffrey
kempler
current
chairman
opthea
decided
retire
opthea
stand
director
opthea
general
meeting
october
mr
kempler
said
behalf
opthea
fellow
directors
welcome
dr
levin
board
delighted
planned
succession
dr
levin
assume
role
chairman
board
upon
retirement
chairman
conclusion
opthea
annual
general
meeting
october
dr
levin
track
record
experience
biotechnology
pharmaceutical
industry
together
knowledge
support
instrumental
company
advances
phase
product
candidate
treatment
wet
macular
degeneration
wet
amd
diabetic
macular
edema
dme
conditions
affect
million
people
opthea
limited
opthea
asx
opt
biopharmaceutical
company
developing
novel
therapy
address
unmet
need
treatment
highly
prevalent
progressive
retinal
diseases
including
wet
macular
degeneration
wet
amd
diabetic
macular
edema
dme
opthea
technology
based
two
members
vascular
endothelial
growth
factor
vegf
family
proteins
activation
vegf
receptors
promote
blood
vessel
development
angiogenesis
vascular
permeability
leakage
binding
activating
also
upregulated
compensate
inhibition
may
represent
important
mechanism
clinical
resistance
monotherapy
opthea
lead
product
candidate
soluble
form
trap
designed
address
deficiency
treatment
paradigm
wet
amd
retinal
diseases
targeting
targeted
current
standard
care
therapies
developed
use
combination
monotherapies
achieve
broader
inhibition
vegf
family
goal
improving
overall
efficacy
demonstrating
superior
vision
gains
achieved
inhibiting
alone
inherent
risks
investment
biotechnology
companies
number
inherent
risks
associated
development
pharmaceutical
products
marketable
stage
lengthy
clinical
trial
process
designed
assess
safety
efficacy
drug
prior
commercialization
significant
proportion
drugs
fail
one
criteria
risks
include
uncertainty
patent
protection
proprietary
rights
whether
patent
applications
issued
patents
offer
adequate
protection
enable
product
development
obtaining
necessary
drug
regulatory
authority
approvals
difficulties
caused
rapid
advancements
technology
companies
opthea
dependent
success
research
development
projects
ability
attract
funding
support
activities
investment
research
development
projects
assessed
fundamentals
trading
manufacturing
enterprises
therefore
investment
companies
specializing
drug
development
must
regarded
highly
speculative
opthea
strongly
recommends
professional
investment
advice
sought
prior
investments
statements
certain
statements
asx
announcement
may
contain
statements
regarding
company
business
therapeutic
commercial
potential
technologies
products
development
statement
describing
company
goals
expectations
intentions
beliefs
statement
considered
statement
statements
subject
certain
risks
uncertainties
particularly
risks
uncertainties
inherent
process
developing
technology
process
discovering
developing
commercializing
drugs
proven
safe
effective
use
human
therapeutics
endeavor
building
business
around
products
services
opthea
undertakes
obligation
publicly
update
statement
whether
result
new
information
future
events
otherwise
actual
results
could
differ
materially
discussed
asx
announcement
